Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment.

Sci Rep · 2025 · PMC12238354 · PMID 40628864

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

showed a trendP = 0.12not close (p > 0.1)

Fatigue showed a trend toward increased risk in the eptinezumab group (RR: 1.92, 95% CI 0.84–4.39, P = 0.12, I 2 = 41%), though it was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.